Vyome Holdings (HIND) Cost of Revenue (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Cost of Revenue of $14946.0 for Q1 2026, down 66.16% year-over-year from $44162.0 in Q1 2025, and up 3.18% quarter-over-quarter from $14485.0 in Q4 2025.
Vyome Holdings (HIND) Cost of Revenue (2015 - 2026) Analysis & Trends
Vyome Holdings' Cost of Revenue history runs 12 years deep, the most recent figure standing at $14946.0 for Q1 2026.
- In Q1 2026, Cost of Revenue fell 66.16% year-over-year to $14946.0; the TTM figure through Mar 2026 stood at $689008.0 (down 25.21% YoY), while the FY2025 annual figure was $100943.0, up 62.88% from the prior year.
- Cost of Revenue for Q1 2026 stood at $14946.0, up from $14485.0 in the prior quarter.
- The five-year high for Cost of Revenue was $1.5 million in Q4 2022, with the low at -$1333.0 in Q4 2024.
- The 5-year median for Cost of Revenue is $697000.0 (2022), against an average of $585722.2.
- The sharpest annual moves came in 2024 and 2025: Cost of Revenue slumped 100.95% in 2024, then jumped 1186.65% in 2025.
- Vyome Holdings' Cost of Revenue stood at $1.5 million in 2022, then sank by 90.73% to $140000.0 in 2023, then slumped by 100.95% to -$1333.0 in 2024, then surged by 1186.65% to $14485.0 in 2025, then climbed by 3.18% to $14946.0 in 2026.
- Business Quant data shows HIND's Cost of Revenue at $14946.0 in Q1 2026, $14485.0 in Q4 2025, and $16577.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | 15,297.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15,297.00 |
| Jun 30, 2026 | 15,297.00 |
| Mar 31, 2026 | 14,946.00 |
| Mar 31, 2026 | 14,946.00 |
| Dec 31, 2025 | 14,485.00 |
| Dec 31, 2025 | 14,485.00 |
| Sep 30, 2025 | 16,577.00 |
| Sep 30, 2025 | 16,577.00 |
| Jun 30, 2025 | 643,000.00 |
| Jun 30, 2025 | 643,000.00 |
| Mar 31, 2025 | 44,162.00 |
| Mar 31, 2025 | 44,162.00 |
| Dec 31, 2024 | -1,333.00 |
| Dec 31, 2024 | -1,333.00 |
| Sep 30, 2024 | 47,441.00 |
| Sep 30, 2024 | 47,441.00 |
| Jun 30, 2024 | 831,000.00 |
| Jun 30, 2024 | 831,000.00 |
| Mar 31, 2024 | 779,000.00 |
| Mar 31, 2024 | 779,000.00 |